Research and Markets has announced the addition of the "Fragile X Syndrome Pipeline Highlights - 2017" drug pipelines to their offering.

This report, Fragile X Syndrome Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Fragile X Syndrome market. It covers emerging therapies for Fragile X Syndrome in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Fragile X Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Fragile X Syndrome pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Fragile X Syndrome pipeline products by the company.

Short-term Launch Highlights:

Find out which Fragile X Syndrome pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Fragile X Syndrome Pipeline by Stages

2. Fragile X Syndrome Pipeline by Drug Class

3. Fragile X Syndrome Pipeline by Company

4. Fragile X Syndrome Phase 3 Clinical Trial Insights

5. Fragile X Syndrome Phase 2 Clinical Trial Insights

6. Fragile X Syndrome Phase 1 Clinical Trial Insights

7. Fragile X Syndrome Preclinical Research Insights

8. Fragile X Syndrome Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/j9c7x8/fragile_x